National Asset Management, Inc. Bio Line Rx Ltd. Transaction History

National Asset Management, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 16, 2024	BUY	$1.03 - $1.56 $2,070 - $3,135	2,010 Added 10.42%	21,300 $23,000
Q4 2023 Mar 15, 2024	SELL	$1.31 - $1.86 $2,633 - $3,738	-2,010 Reduced 9.44%	19,290 $30,000
Q3 2023 Dec 01, 2023	BUY	$1.23 - $2.45 $12,300 - $24,500	10,000 Added 88.5%	21,300 $38,000
Q2 2023 Jul 27, 2023	BUY	$0.96 - $1.78 $10,848 - $20,114	11,300 New	11,300 $18,000

3.3M

46.5K

6.3K

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $29.5M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on National Asset Management, Inc. with notifications on news.